Legend Biotech (LEGN) EBIT Margin (2019 - 2026)

Legend Biotech (LEGN) has 8 years of EBIT Margin data on file, last reported at 16.32% in Q1 2026.

• Quarterly EBIT Margin rose 1019.0% year-over-year to 16.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.64% (up 359.0% YoY) and the FY2025 annual result came in at 13.27%, up 3607.0% from the prior year.
• EBIT Margin declined to 16.32% in Q1 2026, from 6.43% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 473.89% in Q3 2022 to a low of 1581.66% in Q2 2022.
• A 5-year average of 20.16% and a median of 99.96% in 2023 frame the typical range for EBIT Margin.
• Annual changes were most pronounced in 2022 — EBIT Margin slumped 73009 bps — and 2023, when it soared 180558 bps.
• Tracing LEGN's EBIT Margin over 5 years: stood at 405.7% in 2022, then sank by 75 bps to 99.96% in 2023, then slumped by 143 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025, then sank by 154 bps to 16.32% in 2026.
• The last three EBIT Margin figures came in at 16.32% (Q1 2026), 6.43% (Q4 2025), and 15.96% (Q3 2025), per Business Quant data.